- Medicare will start covering Senseonics’ implantable continuous glucose monitor (CGM) for a broader group of patients in late February.
- Three Medicare Administrative Contractors (MACs) — Noridian, Palmetto and National Government Services — finalized local coverage determinations that would cover the devices for people who only take basal insulin, or who don’t take insulin but have a history of hypoglycemia. Previously, they would only cover the CGM for people who took multiple shots of insulin per day.
- Senseonics’ Eversense E3 CGM is implanted under the skin, and it lasts for up to six months. Ascensia is the exclusive global distributor for the device.
